Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients

Almeida, Anne Cristine; Elias, Anna Beatriz Ribeiro; Marques, Maria Paula; Melo, Gisely Cardoso de; Costa, Allyson Guimarães da; Figueiredo, Erick Frota Gomes; Brasil, Larissa Wanderley; Rodrigues-Soares, Fernanda; Monteiro, Wuelton Marcelo; Lacerda, Marcus Vinicius Guimarães de; Lanchote, Vera Lucia; Suarez-Kurtz, Guilherme.
Artículo en Inglés | ARCA | ID: arc-56898

Documentos relacionados

  1. Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients.
  2. Delayed gametocyte clearance in <i>Plasmodium vivax</i> malaria is associated with polymorphisms in the cytochrome P450 reductase (CPR).
  3. A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania.
  4. The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial.
  5. Pyronaridine: a review of its clinical pharmacology in the treatment of malaria.
  6. Molecular Surveillance for Imported Antimicrobial Resistant Plasmodium falciparum, Ontario, Canada.
  7. Molecular detection of drug-resistant <i>Plasmodium falciparum</i> mutants in Assam.
  8. Transition of radical, preventive and presumptive treatment regimens for malaria in China: a systematic review.
  9. Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.
  10. An in vitro toolbox to accelerate anti-malarial drug discovery and development.